直肠癌全程新辅助治疗的依从性与毒性:OPRA试验的二次分析
OPRA试验二次分析比较局部晚期直肠腺癌患者接受诱导化疗后化放疗(INCT-CRT)与化放疗后巩固化疗(CRT-CNCT)的依从性和治疗相关毒性。两组仅启动化放疗和启动全身化疗的比例有轻微差异,完成计划化疗周期数、接受>4500 cGy放疗及3级以上不良事件发生率均无显著差异。依从性和毒性均与器官保留或DFS无关。
要点
- INCT-CRT组启动化放疗比例93% vs CRT-CNCT组98%(P=.03)。
- CRT-CNCT组启动全身化疗比例94% vs INCT-CRT组99%(P=.04)。
- 完成FOLFOX或CAPEOX计划周期数、接受>4500 cGy放疗及3级以上不良事件两组均无显著差异。
核心结论
- INCT-CRT与CRT-CNCT两组在治疗依从性上仅存在轻微差异,不良事件无差异,依从性和毒性均与器官保留率或DFS无关。
研究设计与样本
- OPRA试验的二次分析,纳入临床II/III期直肠腺癌患者324例,随机分配至INCT-CRT组或CRT-CNCT组。
- 全身化疗为8周期(16周)FOLFOX或5周期(15周)CAPEOX,放疗剂量>4500 cGy并同步增敏卡培他滨或氟尿嘧啶。
- 本报告比较两组依从性和治疗相关毒性,并评估化疗依从性、化放疗依从性及毒性与器官保留和DFS的关联。
主要发现
- INCT-CRT组启动化放疗比例93% vs CRT-CNCT组98%(P=.03),CRT-CNCT组启动全身化疗比例94% vs INCT-CRT组99%(P=.04)。
- 完成全部计划FOLFOX周期数比例INCT-CRT组86% vs CRT-CNCT组83%(P=.60),完成全部计划CAPEOX周期数比例INCT-CRT组74% vs CRT-CNCT组77%(P=.80)。
- 接受>4500 cGy放疗比例INCT-CRT组97% vs CRT-CNCT组98%(P=.93)。
- 发生3级以上不良事件比例INCT-CRT组41%(64例)vs CRT-CNCT组34%(57例)(P=.30)。
- 依从性和毒性均与器官保留或DFS无关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with locally advanced rectal cancer treated with total neoadjuvant therapy (TNT) may achieve organ preservation without a compromise to oncologic outcomes. However, reports on patient compliance with TNT and with treatment-related toxicities are limited. METHODS AND MATERIALS: The OPRA trial assessed organ preservation rates and oncologic outcomes in patients with clinical stage II/III rectal adenocarcinoma randomized to induction chemotherapy followed by chemoradiation (INCT-CRT) or chemoradiation followed by consolidation chemotherapy (CRT-CNCT). Systemic chemotherapy consisted of 8 cycles (16 weeks) of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or 5 cycles (15 weeks) of capecitabine and oxaliplatin (CAPEOX). Patients received >4500 cGy of radiation with sensitizing capecitabine or fluorouracil. In this report, we compare compliance and treatment-related toxicity in patients receiving INCT-CRT versus CRT-CNCT. Additionally, we evaluate the association of compliance to chemotherapy, compliance to chemoradiation, and toxicity with organ preservation and disease-free survival (DFS). RESULTS: Of the 324 patients randomized, fewer patients started chemoradiation in the INCT-CRT group compared with the CRT-CNCT group (93% vs 98%, P = .03), and fewer patients started systemic chemotherapy in the CRT-CNCT group compared with the INCT-CRT group (94% vs 99%, P = .04). Order of TNT did not affect the ability to complete all intended cycles of FOLFOX (86% INCT-CRT vs 83% CRT-CNCT, P = .60) or CAPEOX (74% INCT-CRT vs 77% CRT-CNCT, P = .80). A total of 97% of INCT and 98% of CRT-CNCT patients received >4500 cGy radiation (P = .93). Sixty-four patients (41%) treated with INCT-CRT and 57 CRT-CNCT patients (34%) experienced a grade 3+ adverse event (P = .30). Compliance and toxicity were not associated with organ preservation or DFS. CONCLUSIONS: We identified only minor differences in treatment compliance between patients treated with INCT-CRT and CRT-CNCT. No difference in adverse events was observed between groups. Treatment compliance and toxicity did not correlate with organ preservation rates or DFS.
引用
- Verheij FS, Omer DM, Lin ST, et al. Compliance and Toxicity of Total Neoadjuvant Therapy for Rectal Cancer: A Secondary Analysis of the OPRA Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37544412. doi:10.1016/j.ijrobp.2023.07.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。